YSYoungbo Shim

Youngbo Shim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Youngbo Shim has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term outcomes and late complications of intracranial germinoma: Implications for follow-up policy

    by Youngbo Shim, Seung-Ki Kim, Kyung Hyun Kim, Kyung Taek Hong, Chae-Yong Kim, Chul-Kee Park, Ji Yeoun Lee, Ji Hoon Phi, Hee Young Shin, Hyo Seop Ahn, et al.

    Background: We retrospectively assessed the long-term efficacy, safety, and functional outcome of chemotherapy and radiotherapy (RT) in patients with intracranial germinoma (iGE). Methods: A total of 160 patients with iGE treated between 1983 and 2013 were reviewed. Overall survival (OS) was estimated using Kaplan-Meier method. The cumulative incidence of recurrence (CIR), and secondary malignancies (CISM) were analyzed using cumulative incidence functions (CIFs), with death without the event of interest treated as a competing risk. Functional outcomes were assessed using the Karnofsky Performance Scale (KPS). Cox proportional hazards regression was used to analyze predictive factors. Results: The mean follow-up duration was 157.1 months. The 5-/10-year OS rates were 93.8% and 88.6%. The 5- and 10-year CIRs were both 5.6%, whereas the CISM were 0.6% and 2.1%, respectively. Secondary malignancies developed in 14 patients, most commonly glioblastoma. Thirty-one patients died from disease-, treatment-, or secondary malignancy-related causes. Additional causes of death were identified during long-term follow-up, even more than 20 years after treatment. Functional outcomes remained favorable (KPS ≥ 60) in 90.6% at 5 years and 88.5% at 10 years. Chemotherapy combined with reduced extent and reduced-dose RT significantly improved OS without increasing the CIR. Conclusions: Despite the generally favorable prognosis, secondary malignancies and disease- and treatment-related long-term adverse effects significantly affect patient outcomes in iGE. Long-term follow-up (over 20 years) is essential for detecting and managing these complications. Chemotherapy with reduced-extent and reduced-dose RT may help minimize long-term adverse effects.


  • Open Access

    Mild Traumatic Brain Injury as a Heterogeneous Neurological Disorder: Definition, Epidemiology, Neurobiology, and Clinical Course

    by Youngbo Shim, Minwoo Kim, Hong Gyu Yoon, Jong Joo Lee, Je Beom Hong, Yeongu Chung, Jae Keun Oh, Yu Sam Won

    Shim Y, et al. Korean J Neurotrauma. 2026 Apr;22(2):78-88. https://doi.org/10.13004/kjnt.2026.22.e18


  • Open Access

    Role of serum magnesium in post-aneurysmal subarachnoid hemorrhagic hydrocephalus

    by Moinay Kim, Hyunchul Jung, Seung Bin Kim, Jun Ha Hwang, Hanwool Jeon, Yeongu Chung, Youngbo Shim, Jae Hyun Kim, Joonho Byun, Aiden Cousins, et al.

    Background: Post-hemorrhagic hydrocephalus (PHH) is a frequent complication of aneurysmal subarachnoid hemorrhage (aSAH), yet the relationship between serum magnesium (Mg) level and PHH remains unclear. To our knowledge, this is the first prospective study to specifically examine the association between admission serum Mg level and PHH in aSAH patients.Methods: In this prospective, multicenter study (October 2019–October 2024), 131 patients with confirmed aSAH were enrolled from four neuro-intensive care units. Patients were stratified by admission serum Mg level as 2.5 mg/dL correlated with lower PHH incidence in univariate analysis (odds ratio, 0.36; P=0.027) but not in multivariate analysis (P=0.136). Independent predictors of PHH were posterior circulation aneurysm, high Fisher grade, and high Hunt and Hess grade. Poor 30-day mRS was independently associated with high Fisher and Hunt and Hess grades.Conclusions: Admission serum Mg level was not independently associated with PHH, although a potential protective trend was noted at higher levels (>2.5 mg/dL). These findings suggest a possible role of Mg in PHH prevention. Further prospective trials are warranted to clarify the therapeutic potential of Mg and to establish optimal monitoring and correction strategies in aSAH management.


  • Open Access

    Effectiveness of Continuous Intra-Arterial Nimodipine Infusion for the Treatment of Refractory Vasospasm after Aneurysmal Subarachnoid Hemorrhage

    by Hyunbong Lee, Jongjoo Lee, Myung Sub Kim, Jiwook Ryu, Youngbo Shim, Yeongu Chung

    Objective : Delayed cerebral ischemia (DCI) is a severe complication following aneurysmal subarachnoid hemorrhage (aSAH), potentially leading to functional impairments. Cerebral vasospasm (CVS) is one of the primary mechanisms of DCI. In cases of medically refractory CVS, intra-arterial (IA) nimodipine is a rescue treatment, but its effectiveness can be insufficient. We hypothesized that continuous IA nimodipine infusion (CIAN) could serve as a salvage treatment, and we evaluated its effectiveness and safety.Methods : We evaluated 274 patients with aSAH admitted between October 2017 and February 2024, identifying those who received IA nimodipine and those who also received CIAN. Characteristics of the patients, length of stay, and modified Rankin scale (mRS) score at the time of discharge were compared between the conventional IA nimodipine and the CIAN groups.Results : Of the 274 patients, 15 received IA nimodipine, and five of those underwent CIAN. More females were observed in the medically refractory CVS group compared with the non-refractory group (87% [13/15] vs. 66% [171/259]), but there was no sex difference between the CIAN and conventional IA nimodipine groups. CIAN was initiated at a mean of 9 days after the onset of aSAH and continued for 21–81 hours. Two complications were noted, including severe brain edema and suspected heparin-induced thrombocytopenia. However, radiological assessments showed no new lesions. The CIAN group exhibited a longer duration of abnormal findings on transcranial Doppler compared to the conventional IA group (16.0±10.1 vs. 9.4±7.9 days), as well as longer neurocritical care unit (17.4±10.1 vs. 14.1±7.0 days) and hospital stays (46.6±28.7 vs. 29.5±13.2 days). Nonetheless, more achieved a favorable outcome (mRS ≤2) in the CIAN group (80% [4/5] vs. 70% [7/10]).Conclusion : CIAN is a viable salvage treatment for refractory CVS, providing a prolonged vasodilatory effect compared to conventional IA nimodipine, with favorable outcomes.


  • Open Access

    Protein Requirement Changes According to the Treatment Application in Neurocritical Patients

    by Jungook Kim, Youngbo Shim, Yoon-Hee Choo, Hye Seon Kim, Young Ran Kim, Eun Jin Ha

    Objective : Exploring protein requirements for critically ill patients has become prominent. On the other hand, considering the significant impact of coma therapy and targeted temperature management (TTM) on the brain as well as systemic metabolisms, protein requirements may plausibly be changed by treatment application. However, there is currently no research on protein requirements following the application of these treatments. Therefore, the aim of this study is to elucidate changes in patients’ protein requirements during the application of TTM and coma therapy.Methods : This study is a retrospective analysis of prospectively collected data from March 2019 to May 2022. Among the patients admitted to the intensive care unit, those receiving coma therapy and TTM were included. The patient’s treatment period was divided into two phases (phase 1, application and maintenance of coma therapy and TTM; phase 2, tapering and cessation of treatment). In assessing protein requirements, the urine urea nitrogen (UUN) method was employed to estimate the nitrogen balance, offering insight into protein utilization within the body. The patient’s protein requirement for each phase was defined as the amount of protein required to achieve a nitrogen balance within ±5, based on the 24-hour collection of UUN. Changes in protein requirements between phases were analyzed.Results : Out of 195 patients, 107 patients with a total of 214 UUN values were included. The mean protein requirement for the entire treatment period was 1.84±0.62 g/kg/day, which is higher than the generally recommended protein supply of 1.2 g/kg/day. As the treatment was tapered, there was a statistically significant increase in the protein requirement from 1.49±0.42 to 2.18±0.60 in phase 2 (p<0.001).Conclusion : Our study revealed a total average protein requirement of 1.84±0.62 g during the treatment period, which falls within the upper range of the preexisting guidelines. Nevertheless, a notable deviation emerged when analyzing the treatment application period separately. Hence, it is recommended to incorporate considerations for the type and timing of treatment, extending beyond the current guideline, which solely accounts for the severity by disease.


  • Caudal Agenesis: Classification Based on the Pathoembryogenesis of the Spinal Cord

    by Youngbo Shim, Kyung Hyun Kim, Seung-Ki Kim, Kwanjin Park, Seunghyun Lee, Ji Yeoun Lee, Kyu-Chang Wang

    BACKGROUND AND OBJECTIVES: Caudal agenesis (CA) is a congenital disease characterized by lower vertebral bone defects. Previous classifications for CA were based on the levels of bony defects or the conus medullaris. We created a new pathoembryogenic classification that takes into account the level of conus, considering both its shape and filum. We evaluated its accuracy in reflecting the neurological status and the need for untethering. METHODS: Patients with radiologic studies available on our institute's electronic image view system between 1985 and 2019 were reviewed. Our classification categorized patients with CA into 3 groups: the failure of formation (a conus level > L1 or normal level conus with a blunt shape), the failure of regression (a conus level < L3 or normal level conus with a thickened filum or a filar lipoma), and the normal (a normal level conus without specific abnormalities). We analyzed which of the following 3 classifications better reflects the neurological status and the probability of recommending untethering: classifications based on (1) bony defect level, (2) conus level, and (3) pathoembryogenic mechanism. RESULTS: A total of 89 patients were included in this study. The pathoembryogenic classification revealed more significant differences in motor or sensory deficits compared with other classifications (failure of formation: 42%; failure of regression: 16%; and normal: 0%, P = .039). In addition, the pathoembryogenic classification emerged as a significant or suggestive predictive factor for motor and sensory deficits (motor: odds ratio 11.66, P = .007; sensory: odds ratio 5.44, P = .066). Notably, only the pathoembryogenic classification exhibited a significant difference in the probabilities of recommending untethering between groups (failure of formation: 42%; failure of regression: 81%; and normal 12%, P < .001). CONCLUSION: The correlation between bony classification and spinal cord abnormalities was exaggerated. Our new pathoembryogenic classification was valuable in prognosticating neurological status and identifying the patient group more likely to require untethering among patients with CA.


  • Open Access

    Should Hypertonic Saline Be Considered for the Treatment of Intracranial Hypertension? A Review of Current Evidence and Clinical Practices

    by Moowan Park, Youngbo Shim, Yoon-Hee Choo, Hye Seon Kim, Jungook Kim, Eun Jin Ha

    Park M, et al. Korean J Neurotrauma. 2024 Sep;20(3):146-158. https://doi.org/10.13004/kjnt.2024.20.e35


  • Open Access

    The Unique Relationship between Neuro-Critical Care and Critical Illness-Related Corticosteroid Insufficiency : Implications for Neurosurgeons in Neuro-Critical Care

    by Yoon Hee Choo, Moinay Kim, Jae Hyun Kim, Hanwool Jeon, Hee-Won Jung, Eun Jin Ha, Jiwoong Oh, Youngbo Shim, Seung Bin Kim, Han-Gil Jung, et al.

    The brain houses vital hormonal regulatory structures such as the hypothalamus and pituitary gland, which may confer unique susceptibilities to critical illness-related corticosteroid insufficiency (CIRCI) in patients with neurological disorders. In addition, the frequent use of steroids for therapeutic purposes in various neurological conditions may lead to the development of steroid insufficiency. This abstract aims to highlight the significance of understanding these relationships in the context of patient care and management for physicians. Neurological disorders may predispose patients to CIRCI due to the role of the brain in hormonal regulation. Early recognition of CIRCI in the context of neurological diseases is essential to ensure prompt and appropriate intervention. Moreover, the frequent use of steroids for treating neurological conditions can contribute to the development of steroid insufficiency, further complicating the clinical picture. Physicians must be aware of these unique interactions and be prepared to evaluate and manage patients with CIRCI and steroid insufficiency in the context of neurological disorders. This includes timely diagnosis, appropriate steroid administration, and careful monitoring for potential adverse effects. A comprehensive understanding of the interplay between neurological disease, CIRCI, and steroid insufficiency is critical for optimizing patient care and outcomes in this complex patient population.


  • Open Access

    Intracranial Pressure Monitoring for Acute Brain Injured Patients: When, How, What Should We Monitor

    by Youngbo Shim, Jungook Kim, Hye Seon Kim, Jiwoong Oh, Seungioo Lee, Eun Jin Ha

    Shim Y, et al. Korean J Neurotrauma. 2023 Jun;19(2):149-161. https://doi.org/10.13004/kjnt.2023.19.e32


  • Open Access

    Optimizing Mannitol Use in Managing Increased Intracranial Pressure: A Comprehensive Review of Recent Research and Clinical Experiences

    by Jae Hyun Kim, Heewon Jeong, Yoon-Hee Choo, Moinay Kim, Eun Jin Ha, Jiwoong Oh, Youngbo Shim, Seung Bin Kim, Han-Gil Jung, So Hee Park, et al.

    Kim JH, et al. Korean J Neurotrauma. 2023 Jun;19:e25. https://doi.org/10.13004/kjnt.2023.19.e25